Literature DB >> 1540405

HIV regulatory proteins: potential targets for therapeutic intervention.

C A Rosen1.   

Abstract

With the incidence of HIV infection on the rise worldwide, it is obvious that new approaches must be taken to halt the spread of disease. Unfortunately, this is no easy task; of all retroviruses studied to date HIV remains the most complex in terms of genomic organization, regulation of gene expression, and replication. However, as the mechanism of action of the unique viral regulatory proteins is deciphered, new windows of opportunity for attacking the virus like cycle are opened. The essential regulatory function served by both Tat and Rev transacting regulatory proteins makes them attractive targets for prophylactic and therapeutic intervention. This review will focus on our current understanding of Tat and Rev function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540405     DOI: 10.1089/aid.1992.8.175

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  4 in total

1.  Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector.

Authors:  R T Inouye; B Du; D Boldt-Houle; A Ferrante; I W Park; S M Hammer; L Duan; J E Groopman; R J Pomerantz; E F Terwilliger
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

Review 2.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

3.  Cytotoxic T lymphocyte activity and CD8 subpopulations in children at risk of HIV infection.

Authors:  M C Aldhous; K C Watret; J Y Mok; A G Bird; K S Froebel
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

4.  Human immunodeficiency virus type 2 Gag interacts specifically with PRP4, a serine-threonine kinase, and inhibits phosphorylation of splicing factor SF2.

Authors:  Erin M Bennett; Andrew M L Lever; Jane F Allen
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.